Cocrystal Pharma (COCP) Income from Non-Controlling Interests (2010 - 2021)

Cocrystal Pharma (COCP) reported Income from Non-Controlling Interests of $5000.0 for Q1 2021, up 266.67% sequentially from -$3000.0 in Q3 2020.

Cocrystal Pharma (COCP) Income from Non-Controlling Interests (2010 - 2021) Analysis & Trends

Cocrystal Pharma (COCP) has 3 years of Income from Non-Controlling Interests data on file, last reported at $5000.0 in Q1 2021.

For the quarter ending Q1 2021, Income from Non-Controlling Interests changed N/A year-over-year to $5000.0; the trailing twelve-month figure through Mar 2021 stood at $2000.0 (changed N/A YoY), and the FY2020 full-year result was $7000.0, changed N/A from the prior year.
Income from Non-Controlling Interests grew to $5000.0 in Q1 2021, from -$3000.0 in the prior quarter.
In the past five years, Income from Non-Controlling Interests ranged from a high of $5000.0 in Q1 2021 to a low of -$3000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Inc. Minority (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Cocrystal Pharma	12.57 Mn	7.74 Mn	-	-

Download Data